Which has preferable earnings & valuation, IRON or OCS?

Oculis has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Oculis $1.45M 445.05 -$119.44M -$2.13 N/A

Is IRON or OCS more profitable?

Disc Medicine has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Disc Medicine's return on equity of -36.94% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Oculis -8,460.67% -56.78% -45.62%

Does the media favor IRON or OCS?

In the previous week, Disc Medicine had 4 more articles in the media than Oculis. MarketBeat recorded 6 mentions for Disc Medicine and 2 mentions for Oculis. Oculis' average media sentiment score of 1.44 beat Disc Medicine's score of 0.53 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MOR or OCS?

Oculis has a consensus target price of $38.33, suggesting a potential upside of 244.41%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has stronger valuation and earnings, MOR or OCS?

Oculis has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A Oculis $1.45M 445.05 -$119.44M -$2.13 N/A

Is MOR or OCS more profitable?

MorphoSys has a net margin of -226.79% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Oculis -8,460.67% -56.78% -45.62%

Do analysts rate RGC or OCS?

Oculis has a consensus price target of $38.33, suggesting a potential upside of 244.41%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oculis 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has better valuation & earnings, RGC or OCS?

Regencell Bioscience has higher earnings, but lower revenue than Oculis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Oculis $1.45M 445.05 -$119.44M -$2.13 N/A

Does the media prefer RGC or OCS?

In the previous week, Regencell Bioscience had 1 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Regencell Bioscience and 2 mentions for Oculis. Oculis' average media sentiment score of 1.44 beat Regencell Bioscience's score of 0.55 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MBX or OCS more profitable?

MBX Biosciences has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. MBX Biosciences' return on equity of -24.52% beat Oculis' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Oculis -8,460.67% -56.78% -45.62%

Does the media prefer MBX or OCS?

In the previous week, MBX Biosciences had 4 more articles in the media than Oculis. MarketBeat recorded 6 mentions for MBX Biosciences and 2 mentions for Oculis. Oculis' average media sentiment score of 1.44 beat MBX Biosciences' score of 0.29 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, OCS or KOD?

Oculis has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 445.05 -$119.44M -$2.13 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is OCS or KOD more profitable?

Kodiak Sciences has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% Kodiak Sciences N/A -253.85% -81.48%

Oculis (OCS) Competitors

$11.13 -0.31 (-2.71%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$11.11 -0.02 (-0.18%)

As of 07/24/2026 07:34 PM Eastern

Compare

OCS vs. IRON, MOR, RGC, MBX, and KOD

Should you buy Oculis stock or one of its competitors? MarketBeat compares Oculis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oculis include Disc Medicine (IRON), MorphoSys (MOR), Regencell Bioscience (RGC), MBX Biosciences (MBX), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

How does Oculis compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Disc Medicine has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Disc Medicine's return on equity of -36.94% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Oculis	-8,460.67%	-56.78%	-45.62%

In the previous week, Disc Medicine had 4 more articles in the media than Oculis. MarketBeat recorded 6 mentions for Disc Medicine and 2 mentions for Oculis. Oculis' average media sentiment score of 1.44 beat Disc Medicine's score of 0.53 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oculis has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Oculis	$1.45M	445.05	-$119.44M	-$2.13	N/A

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Disc Medicine presently has a consensus price target of $104.44, indicating a potential upside of 40.91%. Oculis has a consensus price target of $38.33, indicating a potential upside of 244.41%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Disc Medicine has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Oculis has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Summary

Disc Medicine and Oculis tied by winning 7 of the 14 factors compared between the two stocks.

How does Oculis compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Oculis has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Oculis	$1.45M	445.05	-$119.44M	-$2.13	N/A

In the previous week, Oculis had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Oculis and 0 mentions for MorphoSys. Oculis' average media sentiment score of 1.44 beat MorphoSys' score of 0.00 indicating that Oculis is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Oculis	Positive

MorphoSys has a net margin of -226.79% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Oculis	-8,460.67%	-56.78%	-45.62%

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Oculis has a consensus target price of $38.33, suggesting a potential upside of 244.41%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oculis beats MorphoSys on 11 of the 16 factors compared between the two stocks.

How does Oculis compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Oculis (NASDAQ:OCS) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

In the previous week, Regencell Bioscience had 1 more articles in the media than Oculis. MarketBeat recorded 3 mentions for Regencell Bioscience and 2 mentions for Oculis. Oculis' average media sentiment score of 1.44 beat Regencell Bioscience's score of 0.55 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Regencell Bioscience's return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Oculis	-8,460.67%	-56.78%	-45.62%

Oculis has a consensus price target of $38.33, suggesting a potential upside of 244.41%. Given Oculis' stronger consensus rating and higher possible upside, analysts clearly believe Oculis is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Regencell Bioscience has higher earnings, but lower revenue than Oculis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Oculis	$1.45M	445.05	-$119.44M	-$2.13	N/A

Regencell Bioscience has a beta of 1.84, suggesting that its stock price is 84% more volatile than the broader market. Comparatively, Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Regencell Bioscience beats Oculis on 7 of the 13 factors compared between the two stocks.

How does Oculis compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Oculis (NASDAQ:OCS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

22.3% of Oculis shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

MBX Biosciences currently has a consensus target price of $66.75, suggesting a potential upside of 7.66%. Oculis has a consensus target price of $38.33, suggesting a potential upside of 244.41%. Given Oculis' stronger consensus rating and higher probable upside, analysts clearly believe Oculis is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

MBX Biosciences has higher earnings, but lower revenue than Oculis. MBX Biosciences is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Oculis	$1.45M	445.05	-$119.44M	-$2.13	N/A

In the previous week, MBX Biosciences had 4 more articles in the media than Oculis. MarketBeat recorded 6 mentions for MBX Biosciences and 2 mentions for Oculis. Oculis' average media sentiment score of 1.44 beat MBX Biosciences' score of 0.29 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. MBX Biosciences' return on equity of -24.52% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Oculis	-8,460.67%	-56.78%	-45.62%

MBX Biosciences has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Oculis has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Summary

Oculis beats MBX Biosciences on 8 of the 15 factors compared between the two stocks.

How does Oculis compare to Kodiak Sciences?

Oculis (NASDAQ:OCS) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Oculis presently has a consensus target price of $38.33, suggesting a potential upside of 244.41%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 1.77%. Given Oculis' stronger consensus rating and higher possible upside, research analysts plainly believe Oculis is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Oculis had 1 more articles in the media than Kodiak Sciences. MarketBeat recorded 2 mentions for Oculis and 1 mentions for Kodiak Sciences. Oculis' average media sentiment score of 1.44 beat Kodiak Sciences' score of 0.94 indicating that Oculis is being referred to more favorably in the media.

Company	Overall Sentiment
Oculis	Positive
Kodiak Sciences	Positive

Oculis has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

Kodiak Sciences has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
Kodiak Sciences	N/A	-253.85%	-81.48%

Oculis has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	445.05	-$119.44M	-$2.13	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

22.3% of Oculis shares are held by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Oculis beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OCS vs. The Competition

Export

Metric	Oculis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$663.34M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-5.23	21.11	27.00	23.71
Price / Sales	445.05	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	2.73	7.88	10.28	6.07
Net Income	-$119.44M	$23.81M	$3.60B	$331.99M
7 Day Performance	-8.70%	-3.82%	-1.29%	-0.61%
1 Month Performance	-5.20%	-2.61%	-0.38%	-1.98%
1 Year Performance	-37.15%	32.79%	18.32%	13.67%

Oculis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OCS Oculis	3.3608 of 5 stars	$11.13 -2.7%	$38.33 +244.4%	-36.9%	$663.34M	$1.45M	N/A	2	Positive News
IRON Disc Medicine	2.0545 of 5 stars	$74.99 -1.3%	$104.44 +39.3%	+22.4%	$2.86B	N/A	N/A	30
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
RGC Regencell Bioscience	0.2632 of 5 stars	$5.58 +10.5%	N/A	-62.3%	$2.75B	N/A	N/A	10
MBX MBX Biosciences	1.739 of 5 stars	$57.05 -5.0%	$60.22 +5.6%	N/A	$2.71B	N/A	N/A	N/A	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OCS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oculis (OCS) Competitors

OCS vs. IRON, MOR, RGC, MBX, and KOD

How does Oculis compare to Disc Medicine?

Summary

How does Oculis compare to MorphoSys?

Summary

How does Oculis compare to Regencell Bioscience?

Summary

How does Oculis compare to MBX Biosciences?

Summary

How does Oculis compare to Kodiak Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oculis (OCS) Competitors

OCS vs. IRON, MOR, RGC, MBX, and KOD

How does Oculis compare to Disc Medicine?

Is IRON or OCS more profitable?

Does the media favor IRON or OCS?

Which has preferable earnings & valuation, IRON or OCS?

Do institutionals & insiders have more ownership in IRON or OCS?

Do analysts prefer IRON or OCS?

Which has more risk & volatility, IRON or OCS?

Summary

How does Oculis compare to MorphoSys?

Which has more volatility & risk, MOR or OCS?

Which has stronger valuation and earnings, MOR or OCS?

Does the media prefer MOR or OCS?

Is MOR or OCS more profitable?

Do insiders & institutionals hold more shares of MOR or OCS?

Do analysts recommend MOR or OCS?

Summary

How does Oculis compare to Regencell Bioscience?

Does the media prefer RGC or OCS?

Is RGC or OCS more profitable?

Do analysts rate RGC or OCS?

Do institutionals and insiders hold more shares of RGC or OCS?

Which has better valuation & earnings, RGC or OCS?

Which has more volatility & risk, RGC or OCS?

Summary

How does Oculis compare to MBX Biosciences?

Do institutionals & insiders hold more shares of MBX or OCS?

Do analysts rate MBX or OCS?

Which has higher earnings and valuation, MBX or OCS?

Does the media prefer MBX or OCS?

Is MBX or OCS more profitable?

Which has more risk and volatility, MBX or OCS?

Summary

How does Oculis compare to Kodiak Sciences?

Do analysts prefer OCS or KOD?

Does the media favor OCS or KOD?

Which has more volatility and risk, OCS or KOD?

Is OCS or KOD more profitable?

Which has better valuation and earnings, OCS or KOD?

Do insiders and institutionals hold more shares of OCS or KOD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCS vs. The Competition

Oculis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools